KHN’s ‘What the Health?’: Dealing With Drug Prices

Published by
Kaiser Health News

Can’t see the audio player? Click here to listen on Acast. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. Medicare officials have preliminarily decided to restrict reimbursement for Aduhelm, the controversial Alzheimer’s drug, to only patients participating in approved clinical trials. The FDA approved the drug in 2021 over objections of the agency’s outside advisers, who complained the evidence of Aduhelm’s efficacy is thin. But the prospect of wide use of the drug — originally priced at $56,000 a year — helped prompt the largest-eve…

Read More

Leave a Reply

Your email address will not be published.